Trial Profile

The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirzepatide (Primary) ; Semaglutide
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

01 Mar 2023 Results assessing the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide published in the Diabetes Care
04 Nov 2022 Results of effect of Tirzepatide on food intake in humans, presented at The Obesity Society: ObesityWeek 2022
23 Sep 2022 Results assessing insulin-sensitizing actions of tirzepatide, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes..

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com